Phreesia stock analysis
Phreesia (0A23) Share Price & Analysis
0A23 Stock Chart & Stats
- Day’s Range
- $10.00 - $10.00
- 52-Week Range
- $10.00 - $28.50
- Previous Close
- $10.00
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- $783.34M
- Enterprise Value
- $665.23M
- Total Cash (Recent Filing)
- $72.94M
- Total Debt (Recent Filing)
- $67.95M
- Price to Earnings (P/E)
- 73.7
- Beta
- 0.10
- Next Earnings
- Dec 02, 2026 (Est.)
- EPS Estimate
- 0.12
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Strong Cash Generation
Strong and rising operating and free cash flow indicate that Phreesia’s platform is increasingly converting revenue into internally funded resources. This supports debt reduction, continued product investment, and greater resilience while the company scales its healthcare software and engagement offerings.
Expanding Client Base And Platform Usage
Growth in both provider clients and revenue per client points to broader adoption and additional monetization within the customer base. This combination supports recurring subscription expansion and usage-based revenue growth, strengthening Phreesia’s position across provider administrative workflows.
Profitability And Margin Inflection
The move from sustained losses to positive earnings, alongside higher gross margins, suggests improving operating leverage and a more scalable economic model. If maintained, this inflection can support durable earnings growth and give management more flexibility to invest in products and customer expansion.
Bears Say
Profitability Remains Thin
Although profitability has improved, the remaining margin cushion is narrow relative to the company’s operating complexity and growth ambitions. Modest pressure on revenue, pricing, or expenses could therefore materially reduce earnings, making sustained execution important over the next several quarters.
Debt Increased From Historical Levels
Recent debt reduction is constructive, but leverage remains higher than in earlier years and increases sensitivity to renewed operating pressure. Interest obligations and repayment needs could constrain capital allocation if cash generation weakens, even though current debt-to-equity remains moderate.
Provider Strain And Pricing Moderation
Provider financial pressure can lengthen sales decisions, limit expansion, and reduce customers’ willingness to accept price increases. Deliberate pricing moderation may support retention and downstream payments, but it can also restrain near-term revenue per client and limit margin expansion.
Phreesia News
0A23 FAQ
What was Phreesia’s price range in the past 12 months?
What is Phreesia’s market cap?
When is Phreesia’s upcoming earnings report date?
How were Phreesia’s earnings last quarter?
Is Phreesia overvalued?
Does Phreesia pay dividends?
What is Phreesia’s EPS estimate?
How many shares outstanding does Phreesia have?
What happened to Phreesia’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Phreesia?
What is the TipRanks Smart Score and how is it calculated?
Phreesia Stock Smart Score
Company Description
Phreesia
Phreesia, Inc. offers a comprehensive, cloud-based software-as-a-service (SaaS) and payment platform specifically designed for the healthcare industry in the United States and Canada. Its flagship Phreesia Platform streamlines the patient intake process and facilitates integrated patient payment processing. The platform is accessible via multiple modalities, including Phreesia Mobile (a patient-facing mobile application), Phreesia Dashboard (a web-based portal for healthcare clients), self-service tablets known as PhreesiaPads, and on-site Arrivals Kiosks. The Phreesia Platform integrates a suite of specialized modules: An automated patient self-registration system. A revenue cycle management solution providing insurance verification, point-of-sale payment applications, and cost estimation tools. Access solutions for online appointment scheduling, reminders, and referral tracking. A life sciences solution delivering targeted, clinically relevant marketing content to patients. Additionally, a clinical support solution gathers clinical intake and patient-reported outcome (PRO) data across approximately 25 specialties, and enables healthcare clients to communicate with patients via surveys, announcements, text and email messaging, and health campaigns. Dedicated COVID-19 support modules assist with vaccine delivery management, identifying vaccine-hesitant individuals, screening for risk factors, facilitating contactless check-in, and managing telehealth visit intake. Phreesia serves a diverse clientele, including individual patients; single and multi-specialty practices, along with health systems; and pharmaceutical, medical device, and biotechnology firms. Established in 2005, the company maintains its headquarters in Raleigh, North Carolina.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- Chaim Indig
- Employees
- 1,789
- Website
- www.phreesia.com
- Address
- 1521 Concord Pike, Wilmington, DE, 19803, US
Phreesia (0A23) Earnings & Revenues
0A23 Company Deck
0A23 Earnings Call
Earnings Call SentimentPositive
The call was strongly constructive, with 10% year-over-year revenue growth, substantial adjusted EBITDA expansion, positive net income for the fifth consecutive quarter, continued positive cash flow, more than $23 million of debt reduction, and reaffirmed fiscal 2027 guidance. AccessOne, Provider Connect, the GLP-1 campaign, and AI initiatives showed encouraging momentum. The main challenges were sequential declines tied to payment-processing seasonality, provider economic strain, pricing moderation, and some earlier volume weakness beyond seasonality.
View all GB:0A23 earnings summaries0A23 Net sales Breakdown
- 45.91% Subscription and related services
- 27.90% Payment processing fees
- 26.19% Network solutions
0A23 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 0 | 3 | 11 |
| Technical Analysis | 0 | 0 | 2 |
| Moving Averages | 0 | 3 | 9 |












